INTRODUCTION
Magnetic resonance (MR) imaging has become widely accepted as the best means to non-invasively evaluate nervous system structures, as it provides outstanding soft tissue contrast and resolution. 1 Over the past two decades, numerous investigations have been performed to define the MR imaging features of various neoplastic, inflammatory, and cerebrovascular brain diseases in veterinary patients. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Data from these reports are often used by clinicians to make presumptive diagnoses and effect treatment strategies. 13 Several studies have demonstrated significant overlap in MR signal characteristics and lesion morphology between divergent intracranial etiologies in dogs. In a recent study using conventional, high-field MR to compare gliomas and cerebral infarcts in dogs, as many as 12%
of histologically confirmed gliomas were incorrectly classified as infarcts. 14 In a population of 41 dogs with histologically confirmed intracranial neoplasia, MR was approximately 90%
sensitive for detecting lesions. 4 In the same report, MR was only 70% sensitive in determining tumor type in dogs with primary brain neoplasia.
Currently, there is insufficient veterinary research to estimate the reliability of MR in the diagnosis of brain disorders of dogs. In one case series of dogs with necrotizing meningoencephalitis, 8 substantial inter-rater agreement was identified in certain aspects of MR lesion detection; however, the study population was small. In a recent abstract, there was strong inter-rater agreement with respect to MR diagnosis in 44 dogs with various brain diseases.
a While these findings are encouraging and supported by results of human studies, veterinary reports have included small populations and assessed agreement using heterogeneous methodology.
The aims of the present study were: (1) to estimate sensitivity and specificity of routine, high-field MR to broadly group canine brain diseases as neoplastic, inflammatory, or cerebrovascular; (2) to estimate sensitivity and specificity of MR to diagnose a subset of specific diseases within broad etiologic categories; (3) to investigate the effect of clinical data on the sensitivity and specificity of brain MR in dogs; and (4) to calculate inter-rater agreement for classification of brain disease in dogs. We hypothesized that sensitivity and specificity of brain MR as well as inter-rater agreement would be high for classifying diseases into general etiologic categories. Given limited veterinary data as well as information from human studies, 15 we hypothesized there would be poorer sensitivity for predicting specific diseases, but that the availability of clinical data would enhance diagnostic performance.
MATERIALS and METHODS

Case Selection
This retrospective case series was a multi-institutional collaboration. All data were entered into a standardized database using commercial spreadsheet software.
b
Histologic Confirmation
Neurohistopathology at each institution was performed by a board-certified pathologist or anatomic pathology resident under their supervision. Tissue sections were stained routinely with hematoxylin and eosin for histologic examination. In a select number of cases with neoplasia, immunohistochemical staining for glial fibrillary acidic protein (GFAP), vimentin, cytokeratin, and CD34 were used to further characterize the histologic diagnosis. All tumors were typed in accordance with World Health Organization recommendations. 16, 17 For dogs with infectious encephalitis, standard bacteriology, viral culture, polymerase chain reaction testing, or immunohistochemical studies were used to determine etiology. Cases histologically diagnosed with more than one neoplastic, inflammatory or cerebrovascular brain disease were also included.
Image Analysis
Brain MR studies were individually assessed for specific requirements to ensure standardization during image analysis. MR study requirements included: (1) After evaluating all images, reviewers sent a copy of their completed responses to one investigator (CW). Reviewers were subsequently given the clinical data obtained from medical records and asked if they wanted to modify their initial response to the following: (1) normal vs.
abnormal MRI study, (2) most likely etiologic category (neoplasia, inflammatory, or cerebrovascular), and (3) most likely specific diagnosis. Reviewers recorded their new response if they elected to modify their initial response based on the available clinical data.
Statistical Analysis
All clinical and imaging data were entered into a spreadsheet program. b Clinical data were summarized using frequencies and descriptive statistics. Sensitivity of detecting a brain lesion was estimated as the proportion of non-epilepsy cases correctly identified as having a true lesion. Specificity of detecting a lesion was estimated as the proportion of epilepsy cases correctly identified as not having a lesion. Category-specific sensitivity was estimated as the proportion of histologically confirmed cases within each category correctly identified as having that lesion type. Specificity was estimated as the proportion of cases within the other categories (excluding epilepsy cases) correctly identified as not having that lesion type. For example, neoplasia-specific sensitivity was estimated as the proportion of cases with confirmed neoplasia correctly identified as having a neoplastic lesion. Specificity was estimated as the proportion of lesions confirmed as not having a neoplastic lesion correctly identified. Diagnosis-specific measures of MR performance were calculated for conditions in which more than a single case was identified. Sensitivity was estimated as the proportion of cases correctly identified and specificity was estimated as the proportion of other etiologies within the same broad diagnostic category correctly identified as not having that disease. The design effect 32 was estimated to account for the dependency among repeated observations and used to adjust confidence intervals (CI). Performance measures were compared with and without clinical data using McNemar's test while accounting for the repeated observations on the same dog. 33 Inter-rater agreement was estimated by calculating the kappa statistic with its associated P value and CI using standard formulas. 34 Ninety-five percent CI for estimates of sensitivity and specificity were calculated using available software.
i
RESULTS
Study Population
The medical records search performed at each of the three collaborating veterinary medical teaching hospitals identified 176 cases. 55 cases were excluded because of a deficient medical record or incomplete MR study, resulting in 121 dogs that met the inclusion criteria ( 
MR detection of broad etiologic categories
Reviewers had a sensitivity of 94.4% (95% CI = 88.7, 97.4) and specificity of 95.5%
(95% CI = 89.9, 98.1) for differentiating MR images of dogs with histologically confirmed 
MR detection of specific etiologies
The estimated sensitivity and specificity for detecting specific diseases varied greatly (Table 2 ). In general, the specificity of MR testing was consistently high across all tumor types CI, confidence interval; SP, specificity; SEN, sensitivity; MRI, magnetic resonance imaging; CPT, choroid plexus tumor; ACA, adenocarcinoma; NST, nerve sheath tumor; GME, granulomatous meningoencephalitis; NE, necrotizing encephalitis; Hemo., hemorrhagic; Isch., ischemic.
for nerve sheath tumor. Sensitivity, however, was consistently much lower for all tumor types.
The highest sensitivity estimates were associated with glioma at 84.4% (95% CI = 66. 4, 94.2) and pituitary tumor at 83.3% (95% CI = 50.9, 97.1). All other neoplastic diseases had sensitivity for detection in the 50-70% range, except lymphoma with a sensitivity estimate of 0% (95% CI = 0, 48.3). Qualitatively, the effects of clinical data on sensitivity and specificity of MR tumor typing appeared small ( Table 2 ). MR diagnostic performance among the inflammatory and cerebrovascular brain diseases showed similar trends to the neoplastic diseases in sensitivity and specificity estimates when clinical data was unknown. Knowledge of clinical data did increase the sensitivity of detecting NE and ischemic infarction, although there was still substantial overlap of both 95% confidence intervals with and without provision of clinical data.
Without provision of clinical data, meningiomas were misclassified in 23 of 57 total responses. Incorrect responses included various other primary and secondary brain neoplasms (n=10), no abnormalities (n=7), unknown (n=5), and bacterial infection (n=1). Gliomas were misclassified in 7 of 45 reviewer responses given without knowledge of clinical data. Glioma misclassifications included unknown (n=3), meningioma (n=1), ependymoma (n=1), GME (n=1), and bacterial infection (n=1). Errors in the classification of inflammatory brain disease and cerebrovascular disease occurred to a greater degree relative to brain neoplasms. Though GME and NE were often correctly reported to be inflammatory in nature, reviewers consistently failed to identify the specific underlying etiology. When clinical data was unknown by reviewers, responses were incorrect in 12 of 24 cases of GME (4 ischemic infarct, 2 unknown, 2 protozoal infection, 2 bacterial infection, 2 NME) and 7 of 15 cases of NE (3 unknown, 3 GME, reviewers. Hemorrhagic infarcts were misclassified in 5 of 9 cases (3 glioma, 2 fungal infection) and ischemic infarcts were misclassified in 7 of 9 cases (3 no abnormalities, 2 glioma, 1 hemorrhagic infarct, 1 unknown) by reviewers without knowledge of clinical data.
Inter-rater agreement
IInter-rater agreements, both with and withour clinical data, were good to very good for 
DISCUSSION
The present study showed that routine, high-field brain MR was a highly sensitive and specific test with very good inter-rater agreement for overall detection of brain lesions, particularly in the detection of neoplastic brain disease in dogs. However, when classifying brain lesions into etiologic categories of inflammatory and cerebrovascular disease, the sensitivity of one study that reported significant variability in MR characteristics of non-neoplastic disease, yet identified seven distinct MR signs that were significantly associated with neoplastic brain disease. 20 In another study comparing MR imaging findings of neoplastic and non-neoplastic canine brain disease, as much as 47% of presumed cerebrovascular accidents were misdiagnosed as gliomas by reviewers who retrospectively reviewed MR images without knowledge of basic case information such as signalment and clinical history. A quality assessment tool for diagnostic accuracy studies (QUADAS) has been developed for use in human medical research. 36 This system evaluates reports for methodological weaknesses such as reviewer bias, lack of a true reference standard, unavailability of clinical information, incorporation bias, and use of an inappropriate patient spectrum. We utilized reviewer blinding, dogs without lesions (epilepsy cases), and dogs with histologically confirmed brain disease to reduce potential limitations.
The importance of judging the validity of a diagnostic test against the gold standard cannot be overstated. Unfortunately two limitations inherent to using histopathologic diagnoses obtained on necropsy or biopsy following abnormal MR imaging include selection bias and use of an inappropriate patient spectrum. 37 Selection bias can occur when the gold standard diagnosis is not obtained independent of the diagnostic test under evaluation. Cases that have undergone surgical biopsy or necropsy to satisfy the histopathologic requirement could represent an inappropriate patient spectrum if their inclusion falsely increases the incidence of abnormal MR images and selects for cases affected with more severe forms of disease. Estimated specificity for lesion detection could have been inflated in the present study because the diagnosis of epilepsy required lack of a structural lesion on MR examination. Another aspect of our study methodology that might be susceptible to selection bias and use of an inappropriate patient spectrum was the evaluation of MR for overall and broad etiologic lesion detection, which raises the possibility of inflated estimates of sensitivity and specificity. Other measures of performance in this study, however, should not be impacted by these elements. In retrospective veterinary and human MR studies, 38 it is inherently challenging to avoid selection bias and use of an inappropriate patient spectrum because of the need to select cases in which MR is commonly used prior to obtaining histopathologic confirmation. Still, our results recapitulate the approximate 90% sensitivity for MR diagnosis of neoplastic brain disease reported in a recent study of 40 dogs with histologically confirmed brain tumors. 
